Zentalis Pharmaceuticals, Inc. Investing Cash Flow
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Investing Cash Flow of $60.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $30.02M, a 1.17% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $30.01M, a 25.85% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $32.45M, a 0.51% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $28.32M, a 41.30% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $131.62M, a 25.45% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $176.56M.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$44.46M.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$114.18M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $60.04M 10-Q · filed 2026-08-06 | $92.49M derived: sum of 3 quarters · filed 2026-08-06 | $120.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $30.01M 10-Q · filed 2026-05-12 | $62.46M derived: sum of 2 quarters · filed 2026-05-12 | $90.78M derived: sum of 3 quarters · filed 2026-05-12 | $121.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $32.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $60.77M derived: sum of 2 quarters · filed 2026-03-26 | $91.15M derived: sum of 3 quarters · filed 2026-08-06 | $131.62M 10-K · filed 2026-03-26 |
| 2025-09-30 | $28.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $58.70M derived: sum of 2 quarters · filed 2026-08-06 | $99.17M 10-Q · filed 2025-11-10 | $131.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $30.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $70.85M 10-Q · filed 2026-08-06 | $103.14M derived: sum of 3 quarters · filed 2026-08-06 | $151.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $40.48M 10-Q · filed 2026-05-12 | $72.76M derived: sum of 2 quarters · filed 2026-05-12 | $121.00M derived: sum of 3 quarters · filed 2026-05-12 | $155.49M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $32.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $80.53M derived: sum of 2 quarters · filed 2026-03-26 | $115.02M derived: sum of 3 quarters · filed 2026-03-26 | $176.56M 10-K · filed 2026-03-26 |
| 2024-09-30 | $48.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $82.73M derived: sum of 2 quarters · filed 2025-11-10 | $144.28M 10-Q · filed 2025-11-10 | $102.22M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $34.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $96.03M 10-Q · filed 2025-08-06 | $53.98M derived: sum of 3 quarters · filed 2026-03-26 | -$63.48M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | $61.55M 10-Q · filed 2025-05-14 | $19.48M derived: sum of 2 quarters · filed 2026-03-26 | -$97.97M derived: sum of 3 quarters · filed 2026-03-26 | -$25.03M derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | -$42.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$159.51M derived: sum of 2 quarters · filed 2026-03-26 | -$86.58M derived: sum of 3 quarters · filed 2026-03-26 | -$44.46M 10-K · filed 2026-03-26 |
| 2023-09-30 | -$117.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$44.52M derived: sum of 2 quarters · filed 2024-11-12 | -$2.40M 10-Q · filed 2024-11-12 | -$14.29M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $72.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $115.05M 10-Q · filed 2024-08-09 | $103.16M derived: sum of 3 quarters · filed 2025-03-26 | $123.18M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $42.12M 10-Q · filed 2024-05-07 | $30.23M derived: sum of 2 quarters · filed 2025-03-26 | $50.24M derived: sum of 3 quarters · filed 2025-03-26 | -$91.86M derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | -$11.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $8.12M derived: sum of 2 quarters · filed 2025-03-26 | -$133.98M derived: sum of 3 quarters · filed 2025-03-26 | -$114.18M 10-K · filed 2025-03-26 |
| 2022-09-30 | $20.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$122.08M derived: sum of 2 quarters · filed 2023-11-06 | -$102.29M 10-Q · filed 2023-11-06 | -$59.02M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$142.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$122.30M 10-Q · filed 2023-08-09 | -$79.04M derived: sum of 3 quarters · filed 2024-02-27 | -$220.48M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $19.80M 10-Q · filed 2023-05-10 | $63.06M derived: sum of 2 quarters · filed 2024-02-27 | -$78.38M derived: sum of 3 quarters · filed 2024-02-27 | -$11.78M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $43.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$98.18M derived: sum of 2 quarters · filed 2024-02-27 | -$31.57M derived: sum of 3 quarters · filed 2024-02-27 | -$18.11M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$141.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$74.84M derived: sum of 2 quarters · filed 2022-11-09 | -$61.38M 10-Q · filed 2022-11-09 | -$71.03M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $66.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $80.06M 10-Q · filed 2022-08-09 | $70.41M derived: sum of 3 quarters · filed 2023-03-01 | -$67.48M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $13.46M 10-Q · filed 2022-05-05 | $3.81M derived: sum of 2 quarters · filed 2023-03-01 | -$134.08M derived: sum of 3 quarters · filed 2023-03-01 | -$271.34M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$9.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$147.54M derived: sum of 2 quarters · filed 2023-03-01 | -$284.80M derived: sum of 3 quarters · filed 2023-03-01 | -$284.83M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$137.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$275.15M derived: sum of 2 quarters · filed 2021-11-10 | -$275.18M 10-Q · filed 2021-11-10 | -$275.22M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$137.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$137.29M 10-Q · filed 2021-08-12 | -$137.33M derived: sum of 3 quarters · filed 2022-02-24 | -$137.44M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$31.00K 10-Q · filed 2021-05-17 | -$67.00K derived: sum of 2 quarters · filed 2022-02-24 | -$174.00K derived: sum of 3 quarters · filed 2022-02-24 | -$342.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$143.00K derived: sum of 2 quarters · filed 2022-02-24 | -$311.00K derived: sum of 3 quarters · filed 2022-02-24 | -$352.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | -$107.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$275.00K derived: sum of 2 quarters · filed 2020-11-09 | -$316.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | -$168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$209.00K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | -$41.00K 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |